Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Author:
Affiliation:
1. Department of Family Medicine, University of Texas Health Science Center, San Antonio, USA
2. Unger Primary Care Concierge Medical Group, Rancho Cucamonga, USA
Funder
Novo Nordisk Inc. Plainsboro, NJ
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/00325481.2021.1971461
Reference115 articles.
1. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
2. Change in Testing, Awareness of Hemoglobin A1c Result, and Glycemic Control in US Adults, 2007-2014
3. Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers
4. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
5. Shared decision-making and outcomes in type 2 diabetes: A systematic review and meta-analysis
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease;GeroScience;2024-04-02
2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE);Clinical Drug Investigation;2024-03-20
3. Effects of liraglutide on ANP secretion and cardiac dynamics;Endocrine Connections;2023-09-07
4. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules;International Journal of Biological Macromolecules;2023-07
5. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes;Diabetes, Obesity and Metabolism;2023-02-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3